Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of SAR445399 in moderate to severe hidradenitis suppurativa
jRCT2031250733Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Mar 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of SAR445399 in hidradenitis suppurativa (HS) (3 arms), sponsored by Sanofi. Started Mar 2026; status: recruiting.
02
Drugs
SAR445399
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2031250733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250733.